BioCryst Pharmaceuticals, Inc.

NasdaqGS:BCRX Voorraadrapport

Marktkapitalisatie: US$1.6b

BioCryst Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

De CEO BioCryst Pharmaceuticals is Jon Stonehouse, benoemd in Jan2007, heeft een ambtstermijn van 17.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.78M, bestaande uit 13.9% salaris en 86.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.43% van de aandelen van het bedrijf, ter waarde $ 6.71M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.7 jaar en 5.3 jaar.

Belangrijke informatie

Jon Stonehouse

Algemeen directeur

US$4.8m

Totale compensatie

Percentage CEO-salaris13.9%
Dienstverband CEO17.8yrs
Eigendom CEO0.4%
Management gemiddelde ambtstermijn4.7yrs
Gemiddelde ambtstermijn bestuur5.3yrs

Recente managementupdates

Recent updates

BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)

Sep 29

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29
Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo

Oct 11

BioCryst Pharmaceuticals promotes Sheridan to development chief

Sep 14

BioCryst wins FDA’s Orphan Drug status for bone disorder therapy

Aug 31

BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M

Aug 25

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

Analyse CEO-vergoeding

Hoe is Jon Stonehouse's beloning veranderd ten opzichte van BioCryst Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$124m

Jun 30 2024n/an/a

-US$146m

Mar 31 2024n/an/a

-US$209m

Dec 31 2023US$5mUS$666k

-US$227m

Sep 30 2023n/an/a

-US$236m

Jun 30 2023n/an/a

-US$243m

Mar 31 2023n/an/a

-US$226m

Dec 31 2022US$7mUS$640k

-US$247m

Sep 30 2022n/an/a

-US$193m

Jun 30 2022n/an/a

-US$210m

Mar 31 2022n/an/a

-US$194m

Dec 31 2021US$7mUS$583k

-US$184m

Sep 30 2021n/an/a

-US$227m

Jun 30 2021n/an/a

-US$214m

Mar 31 2021n/an/a

-US$209m

Dec 31 2020US$6mUS$567k

-US$183m

Sep 30 2020n/an/a

-US$125m

Jun 30 2020n/an/a

-US$116m

Mar 31 2020n/an/a

-US$115m

Dec 31 2019US$2mUS$550k

-US$109m

Sep 30 2019n/an/a

-US$134m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$107m

Dec 31 2018US$4mUS$550k

-US$101m

Sep 30 2018n/an/a

-US$93m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$77m

Dec 31 2017US$4mUS$533k

-US$66m

Compensatie versus markt: De totale vergoeding ($USD 4.78M ) Jon } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Jon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jon Stonehouse (63 yo)

17.8yrs

Tenure

US$4,777,778

Compensatie

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jon Stonehouse
CEO, President & Executive Director17.8yrsUS$4.78m0.43%
$ 6.7m
Anthony Doyle
Senior VP4.6yrsUS$1.79m0.082%
$ 1.3m
Alane Barnes
Senior VP18.2yrsUS$1.93m0.089%
$ 1.4m
Helen Thackray
Chief Research & Development Officer3.7yrsUS$2.39m0.055%
$ 861.7k
Charles Gayer
Senior VP & Chief Commercial Officer4.8yrsUS$1.74m0.10%
$ 1.6m
John Bluth
Chief Communications Officerno datageen gegevensgeen gegevens
Stephanie Angelini
Chief People Officerno datageen gegevensgeen gegevens
William Sheridan
Chief Development Officer16.3yrsUS$2.66mgeen gegevens
Yarlagadda Babu
Chief Discovery Officer11.1yrsUS$2.57mgeen gegevens
Jinky Rosselli
Chief Data & Insights Officer3yrsgeen gegevensgeen gegevens
Philip George
Chief Strategy Officer2.2yrsgeen gegevensgeen gegevens
Clayton Fletcher
Chief Business Development Officer1.8yrsgeen gegevensgeen gegevens

4.7yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BCRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jon Stonehouse
CEO, President & Executive Director17.8yrsUS$4.78m0.43%
$ 6.7m
Vincent Milano
Independent Director3.3yrsUS$434.82k0.033%
$ 520.7k
Stephen Aselage
Independent Director5.8yrsUS$446.90k0.024%
$ 373.1k
Alan Levin
Independent Director4.8yrsUS$434.54k0.014%
$ 214.4k
George Abercrombie
Independent Director13.1yrsUS$432.74k0.0062%
$ 97.8k
Theresa Heggie
Independent Director5.9yrsUS$433.57k0.022%
$ 349.8k
Nancy Hutson
Independent Chair12.8yrsUS$470.30k0.034%
$ 532.6k
Steven K. Galson
Independent Director3.2yrsUS$424.40k0.017%
$ 264.5k
A. Sanders
Independent Director2.8yrsUS$423.15k0.010%
$ 159.0k
Amy McKee
Independent Director3.2yrsUS$422.32k0.010%
$ 159.6k

5.3yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BCRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).